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ABSTRACT 
Background: Mammographic density is a strong heritable trait, but data on its genetic component 
are limited to area-based and qualitative measures. We studied the heritability of volumetric 
mammographic density ascertained by a fully-automated method and the association with breast 
cancer susceptibility loci. 
Methods: Heritability of volumetric mammographic density was estimated with a variance 
component model in a sib-pair sample (N pairs = 955) of a Swedish screening based cohort. 
Associations with 82 established breast cancer loci were assessed in an independent sample of the 
same cohort (N = 4,025 unrelated women) using linear models, adjusting for age, body mass index 
and menopausal status. All tests were two-sided, except for heritability analyses where one-sided 
tests were used. 
Results: After multivariable adjustment, heritability estimates (standard error) for percent dense 
volume, absolute dense volume and absolute nondense volume were 0.63 (0.06) and 0.43 (0.06) and 
0.61 (0.06) respectively (all P < 0.001). Percent and absolute dense volume were associated with 
rs10995190 (ZNF365; P = 9.0x10-6 and 8.9x10-7 respectively) and rs9485372 (TAB2; P = 1.8x10-5 and 
1.8x10-3 respectively). We also observed associations of rs9383938 (ESR1) and rs2046210 (ESR1) with 
the absolute dense volume (P = 2.6x10-4 and 4.6x10-4 respectively), and rs6001930 (MLK1) and 
rs17356907 (NTN4) with the absolute nondense volume (P = 6.7x10-6 and 8.4x10-5 respectively).  
Conclusions: Our results support the high heritability of mammographic density, though estimates 
are weaker for absolute than percent dense volume. We also demonstrate that the shared genetic 
component with breast cancer is not restricted to dense tissues only.   
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INTRODUCTION 
Mammographic density which reflects the amount of fibroglandular or radio-dense tissue in the 
breast is a strong determinant of breast cancer risk (1). Although the exact mechanisms underlying 
the association between mammographic density and breast cancer are not completely understood, 
both traits share several risk factors including nulliparity, late age at first birth and hormone 
replacement therapy (HRT) (2,3). Apart from an overlap in environmental risk factors, there is also 
evidence of a shared genetic basis. Twin studies estimate that approximately 60% of the variation in 
mammographic density is genetically determined (4,5) and the polygenic mode of inheritance 
suggests that both traits share a large number of genetic variants (6). To date, five single nucleotide 
polymorphisms (SNPs) which have been reported to be associated with mammographic density 
[rs10995190 in ZNF365, rs2046210 at 6q25 near ESR1 (7), rs3817198 in LSP1, rs10483813 in RAD51L1 
(8), rs13281615 at 8q24 (9)] had previously been identified as breast cancer susceptibility SNPs, 
whilst only one SNP [rs1265507 at 12q24 (10)] has been reported as being associated with 
mammographic density but not with breast cancer. Last year, 41 new breast cancer loci were 
discovered in a large collaborative effort (11), enlarging the pool of candidate SNPs for further 
analysis of mammographic density. 
Thus far, all studies investigating the genetic basis of mammographic density have used either 
qualitative or semi-automated area-based measures (4,5,12-16). The main disadvantage of these 
measures is that they are reader-dependent and do not acknowledge the 3D structure of the breast. 
Fully-automated measures of volumetric mammographic density may provide more accurate 
measures as they incorporate information on breast thickness (17,18). Studies comparing volumetric 
to area-based measures show good agreement for percent mammographic density, but the 
correlation for the absolute dense tissue is weak (19-23). These data underscore the notion that both 
methods measure different aspects of the same underlying entity.  
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In the present study, we aimed to estimate the heritability of volumetric mammographic density and 
to explore the shared genetic component with breast cancer by analyzing associations with 
established breast cancer susceptibility loci.  
 
METHODS 
 
Study population 
The KARolinska MAmmography project for risk prediction of breast cancer (KARMA) is a prospective 
cohort study initiated in January 2011 and comprises 70,866 women attending mammography 
screening or clinical mammography at four hospitals in Sweden (24). Upon study entry, participants 
responded to a web-based questionnaire, donated blood and gave permission for storage of raw full 
field digital mammograms. 
We used two study populations to address our research questions. We used a sib-pair design for the 
heritability analysis including all full and half-sib pairs in KARMA. Since all women in Sweden have a 
unique national registration number, sister-relations can be retrieved through the Multiple 
Generation Register. We only considered female blood relatives for this analysis and excluded twins 
as their number was too small for having a meaningful contribution. We selected a separate  
independent sample for the breast cancer SNP analysis including unrelated women who were 
genotyped using the custom Illumina iSelect genotyping array (iCOGS, details described below).  
The same selection criteria were applied to both samples. We included all women with raw digital 
mammograms who were in the age range for mammography screening in Sweden (40-74 years). We 
excluded women who had previous cancers other than non-melanoma skin cancer, women with 
breast enlargements/reductions/surgery and participants who were pregnant in the twelve months 
prior to study entry. We further excluded women with incomplete questionnaire data and missing 
information on age, BMI and menopausal status, as well as sisters with incomplete covariate data. 
This resulted in a study population of 955 sib-pairs (908 full-sib and 47 half-sib pairs) for the 
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heritability analysis and 4,025 unrelated women for the breast cancer SNP analysis. The study was 
approved by the ethical review committee at Karolinska Institutet and all participants provided 
written informed consent. 
 
Mammographic density measures 
Mammographic density was measured from the medio-lateral oblique (MLO) view using a fully 
automated volumetric method (VolparaTM, version 1.4.3). Technical details of the software have been 
described elsewhere (17). In brief, the algorithm computes the thickness of dense tissue at each pixel 
using the X-ray attenuation of an entirely fatty region as an internal reference. The absolute dense 
volume (cm3) is measured by integrating the dense thickness at each pixel over the whole 
mammogram and the total breast volume (cm3) is derived by multiplying the breast area by the 
recorded breast thickness, with an appropriate correction for the breast edge. Percent dense volume 
(%) is obtained from the ratio of these two measures, and the absolute nondense volume (cm3) from 
subtracting the absolute dense volume from the total breast volume. 
Volpara has been validated against breast magnetic resonance imaging (MRI) data and the method 
appears to be robust to changes in imaging conditions (17). Moreover, we have recently shown that 
Volpara performs well in a high-throughput setting with both percent and absolute dense volume 
being associated with established density determinants and breast cancer risk (25). 
 
Covariates 
Participants filled out a detailed web-based questionnaire including information on reproductive 
history, use of hormone replacement therapy (HRT) and previous benign breast disease. Menopausal 
status was defined according to information on menstruation status, previous oophorectomy and age 
at study entry. Postmenopausal women were defined as those who had no periods during the last 
year, a history of oophorectomy, or age 55 or older. Women were considered premenopausal when 
they reported having periods during the past 3 months or age < 46 years if they had missing data on 
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menstruation status. Body mass index (BMI) was calculated based on self-reported height and 
weight. We also collected information on body size at age 7 and 18 years by means of a nine-level 
somatotype, a method that has previously been validated against BMI data (26). 
 
Genotyped and imputed SNP data 
Genotyping was performed using the iCOGS array. This array comprises 211,155 SNPs which were 
primarily selected for replication of loci putatively associated with breast, ovarian or prostate cancer 
(11). Standard SNP quality control was performed in Plink (version 1.07) (27) and SNPs with call rates 
< 95% and/or deviation from Hardy–Weinberg equilibrium (HWE) at P < 1x10-5 were excluded. 
For the breast cancer SNP analysis, we considered all common variants linked to breast cancer at a 
genome-wide significance level (P < 5 x 10-8) in COGS (11,28) or previous genome-wide association 
studies (GWAS) as identified through the GWAS catalog (29). We also included SNPs that were 
identified in recent fine-mapping studies of the TERT and 11q13 regions (30,31). In total 82 
established breast cancer SNPs were identified. All variants were genotyped directly, except for 6 
(rs11242675, rs2180341, rs9485372, rs11814448, rs2284378 and rs13393577) which were imputed 
using IMPUTE v2 using the 1000 Genomes Project March 2012 release as a reference. 
(32). All imputed SNPs passed quality control (INFO-score > 0.80).  
 
Statistical analysis 
All mammographic measures were log-transformed prior to analyses to approximate the normal 
distribution. We first estimated full and half sib-pair correlations by calculating intra-class correlation 
coefficients (ICCs) between the residuals of each mammographic measure. Three models were used 
to study the influence of potential confounders. We started with a model adjusting for age and 
menopausal status, after which BMI was added in a second model. Age at menarche, HRT, history of 
benign breast disease, parity and age at first birth were then added to the final multivariable 
adjusted model. We also performed a sensitivity analysis with additional adjustment for height and 
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body size at age 7 and 18 years. Previous studies have shown that adjustment for all relevant 
covariates is important, not only to account for potential overestimation of genetic  influences by 
shared environmental factors, but also to reduce noise as covariates can influence the variability of 
the trait (16).  
Heritability was estimated by fitting variance-component models as implemented in the Sequential 
Oligogenic Linkage Analysis Routines package (SOLAR, version 7.2.5.) (33,34). This approach is based 
on maximum likelihood estimation of a linear mixed-effects model incorporating fixed covariate 
effects, additive genetic effects and residual error. According to this model, each mammographic 
value Pi   for individual i can be written as a linear function of the following form: 
 
 Pi = μ +  ∑  
 
   βj vij   + gi    + ei    
 
where μ is the overall mean and βj is the regression coefficient of the jth individual specific covariate 
which takes value vij for the ith individual. The values of gi and ei represent deviations from μ that are 
due to additive genetic effects and residual error respectively, and are assumed to be independently 
normally distributed. Heritability (h2) in this case is narrow sense heritability, defined as the ratio of 
the variance of the additive genetic effects to the total (residual) variance in mammographic density. 
Breast cancer SNP analyses were performed using tests for genotype trend effects in linear 
regression models with mammographic density as outcome and adjusting for age, BMI and 
menopausal status. For imputed SNPs, allele dosages were used in place of genotype calls. We also 
estimated the proportion of variance explained by all breast cancer SNPs.  
Statistical tests for heritability were necessarily one-sided (H1:  ICC > 0 and H1: h2 > 0), while tests for 
breast cancer SNP associations were all two-sided. A Bonferroni correction was applied in the breast 
cancer SNP analysis to account for multiple testing with the threshold of statistical significance being 
defined as P = 6.10 x 10-4 (= 0.05 divided by 82). We also calculated a more conservative threshold of 
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P = 2.03 x 10-4 [0.05 / (82 x 3)] based on further correction for the three different (albeit) related 
outcomes and we carefully interpreted SNPs with P  values between 6.10 x 10-4 and 2.03 x 10-4. 
 
RESULTS 
 
Participant characteristics are summarized in Table 1. Both populations had a mean age at study 
entry of 54 years and a mean BMI of 25 kg/m2. Geometric means (95% CI) of percent dense volume, 
absolute dense volume and absolute nondense volume were 7.8 (4.5-11.2), 57 (54-60) and 662 (658-
666) respectively in the KARMA sisters. The corresponding values were 8.4 (5.1-11.7), 60 (57-63) and 
646 (642-649) in the sample of unrelated women with SNP data. The majority of KARMA sisters were 
full-sisters, with only a small proportion being half-sib (4.9%). 
 
Sister-pair correlations and heritability of volumetric mammographic density 
Overall, sib-pair correlations were stronger for percent than absolute dense volume. In full sisters, 
age and menopause adjusted ICCs (SE) for percent dense volume and absolute dense volume were 
0.30 (0.03) and 0.21 (0.03) respectively (all P < 0.001). The full-sib correlation for the absolute 
nondense volume was similar to the ICC for percent dense volume [0.31 (0.03)]. Adjustment for BMI 
and other covariates did not influence the sib-pair correlations (Table 2). Although ICCs were less 
precise in half-sibs due to the small number of pairs, the multivariable adjusted ICC (SE) for percent 
dense volume [0.16 (0.14)] and absolute dense volume [0.11 (SE 0.14)] were approximately half of 
those found in full-sibs. Heritability analyses showed similar results, with stronger heritability 
estimates for percent than absolute dense volume. After multivariable adjustment heritability 
estimates (SE) for percent dense volume, absolute dense volume and absolute nondense volume 
were 0.63 (0.06), 0.43 (0.06) and 0.61 (0.06) respectively (Table 2). Results remained unchanged after 
additional adjustment for height and body size at age 7 and 18 years (data not shown). 
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Associations with established breast cancer susceptibility loci 
Results from the breast cancer SNP analysis are shown in Table 3. Four breast cancer SNPs were 
found to be associated with volumetric mammographic density. The strongest association was 
observed for rs10995190 in the ZNF365 gene, with betas (SE) per minor allele increase being -0.05 
(0.01) for percent dense volume (P = 9.0x10-6) and -0.07 (0.01) for absolute dense volume (P = 8.9x10-
7). We also found associations of rs9485372 in the TAB2 gene with percent dense volume (P = 1.8x10-
5) and absolute dense volume (P = 1.8x10-3), although the latter association was not statistically 
significant. The corresponding betas (SE) per minor allele increase were -0.09 (0.02) and -0.08 (0.03) 
respectively. Furthermore, two SNPs (rs9383938 in the ESR1 gene and rs2046210 upstream of ESR1) 
were associated with the absolute dense volume, but not with percent dense volume: beta (SE) per 
minor allele increase = 0.07 (0.02) for rs9383938 (P = 2.6x10-4) and 0.04 (0.01) for rs2046210 (P = 
4.6x10-4).  
We also explored associations with the absolute nondense volume and found associations with 
rs6001930 in the MKL1 gene (P = 6.7x10-6) and rs17356907 near the NTN4 (P = 8.4x10-5).  
All breast cancer SNP associations exceeded the primary and more conservative P value threshold, 
except for rs9383938 and rs2046210 which were only statistically significant at the primary P value 
threshold.  
When fitted together, the established breast cancer SNPs explained 4.3% of the variance in absolute 
dense volume. This percentage was lower for percent dense volume and the absolute nondense 
volume (2.2% and 1.6% respectively). 
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DISCUSSION 
 
We observed high heritability values for volumetric mammographic density, though estimates were 
weaker for absolute than percent dense volume. We could replicate previously observed associations 
of rs10995190 (ZNF365) and rs2046210 (ESR1) with mammographic density, and identified novel 
associations with breast cancer SNPs in 6q25: rs9485372 (TAB2) and rs9383938 (ESR1). We also 
found evidence of breast cancer SNP associations with the absolute nondense volume: rs6001930 
(MKL1) and rs17356907 (NTN4).   
Previous studies using area-based mammographic measures (4,5,12,14,16,35) have shown 
comparable estimates for percent and absolute mammographic density. In the Sisters in Breast 
Screening Study (SIBS) h2 values of 0.63 and 0.66 were observed for percent and absolute dense area 
respectively (35). In our study using volumetric measures, we found a similar heritability estimate for 
percent dense volume (h2 = 0.63), but a weaker estimate for the absolute dense volume (h2 = 0.43). 
This difference in heritability between absolute dense area and absolute dense volume is not totally 
unexpected and complements previous data showing good agreement between area-based and 
volumetric methods for percent density, but weaker correlations for the absolute dense tissue (19-
23). In fact, both measures represent different aspects of mammographic density, as area-based 
methods reduce mammographic density to projected areas where pixels represent either dense or 
non-dense tissue, while volumetric methods account for breast thickness by estimating the relative 
amount of density in each individual pixel. The incorporation of breast thickness is also reflected in 
the differential association with BMI. BMI is inversely related to the absolute dense area, but shows a 
positive association with the absolute dense volume (19,21-23). Altogether these results suggest that 
absolute dense area and volume have unique features, not only regarding the association with BMI 
but also in terms of heritability. 
Results of our breast cancer SNP analyses are partly in line with those previously reported for area-
based measures. The minor allele of rs10995190 in the ZNF365 gene was found to be associated with 
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a lower percent dense area in the first GWAS of mammographic density (7); accordingly, we found 
the minor allele to be associated with lower percent and absolute dense volume. In addition, the 
minor allele of rs2046210 on chromosome 6q25 (upstream of the ESR1 gene) is known to be 
associated with higher percent and absolute dense area (7); we found it to be associated with higher 
absolute dense volume, but saw no association with percent dense volume (P = 0.27). Furthermore, 
no associations were observed with other SNPs that have previously been linked to area-based 
density in non-GWAS approaches (i.e. rs3817198 in the LSP1 gene, rs13281615 at chromosome 8q24 
and rs10483813 in the RAD51L1 gene) (7-9). There are several possible explanations for the 
differences between our findings and those obtained using area-based measures. Firstly, it is 
important to bear in mind that whilst both mammographic dense area and dense volume attempt to 
capture the same information about breast composition, they are distinct measures of 
mammographic density. An alternative explanation may lie in differences between study populations. 
Recent data show that the effect of breast cancer SNPs varies according to other environmental 
factors (36) and this kind of heterogeneity may explain the lack of an overall association found in this 
study. A third explanation is the statistical power of the different studies. Our study had 90% power 
to detect a 1% absolute difference in percent dense volume between homozygous carriers and non-
carriers of a SNP with a minor allele frequency (MAF) of 0.16 e.g. rs10995190 (ZNF365). We had 
higher statistical power to detect similar effects for more common SNPs. However, our study could 
have been underpowered when the effect sizes of the SNPs are much smaller than the effect of the 
ZNF365 SNP. 
Interestingly, we found evidence of two novel breast cancer SNP associations with mammographic 
density at 6q25: rs9383938 and rs9485372. Rs9383938 is located in the ESR1 gene and despite being 
in close proximity to rs2046210, both SNPs are not strongly correlated (R2 = 0.12). Rs9485372 is 
located in the TGF-beta activated kinase 1/MAP3K7 binding protein 2 (TAB2) gene and has been 
associated with breast cancer risk in Asian women (39). The underlying biology of this association 
remains to be determined, but the TGF-beta pathway plays an important role in early tumorigenesis 
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and metastasis (40,41) as well as mammary development (42). The TAB2 protein also interacts 
directly with the N-terminal domain of ESR1 and has been implicated in pro-inflammatory induced 
re-activation of repressed estrogen receptor signalling pathways (43,44). 
For all SNPs described above, associations were in the same direction as their effect on breast cancer 
risk (11,39,45). In addition, we found two breast cancer SNP associations for the absolute nondense 
volume: rs17356907 near the NTN4 gene and rs6001930 in the MKL1 gene. Both SNPs have 
previously been associated with an area-based measure of breast size (46), but not specifically with 
the nondense volume. The direction of both associations is opposite to those reported for breast 
cancer (11), supporting the idea that the absolute nondense volume exerts a protective effect on 
breast cancer risk (47,48).  
Our study has several strengths and weaknesses. We used a fully automated density method which is 
expected to be less prone to measurement errors. Furthermore, SNP analyses were performed in 
cancer-free women, reducing the likelihood of artificial associations due to confounding by breast 
cancer (49,50). The heritability analysis was confined to full and half-sisters only. We could not 
retrieve cousin relations in our cohort, as this would require three generation pedigree information 
which is not available in the Multiple Generation Register. Also, we did not consider mother-daughter 
relations for our analysis, as this number would be very small given the age range for mammography 
screening. Further, it should be noted that genetic correlations among sisters could be affected by 
shared environmental effects. Heritability estimates were not materially different after adjusting for 
known determinants of mammographic density. Thus, inflation of our estimates due to these factors 
is unlikely, although we cannot rule out potential inflation by unmeasured shared environmental 
factors.   
In conclusion, our results confirm the high heritability of mammographic density, though estimates 
are weaker for absolute than percent dense volume. These data support the notion that 
mammographic density is a risk factor under strong genetic influence that may partially explain the 
familial aggregation of breast cancer. The breast cancer SNPs that have been identified to date 
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explain only little of the variation in mammographic density, but the observed associations with 
individual SNPs are relevant as they provide more insight into the biological mechanisms leading to 
breast cancer in women with high dense breasts. In addition, the observed breast cancer SNP 
associations with the absolute nondense volume indicate that the shared genetic component with 
breast cancer is not restricted to dense tissues only.  
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Table 1. Characteristics of the study populations.  
 
Participant characteristic Karma sisters 
(N = 1,910) 
Karma iCOGS 
(N = 4,025) 
Age (years) 54.3 (9.1) 54.6 (9.4) 
Body mass index (kg/m2) 25.5 (4.5) 25.3 (4.2) 
Age at menarche (years) 13.2 (1.5) 13.1 (1.4) 
Age at first birth (years) 26.5 (4.9) 27.0 (5.0) 
   
Number of births, % (N)   
 0 11.7 (224) 12.9 (518) 
 1 12.3 (234) 14.6 (587) 
 2  47.0 (898) 46.2 (1,860) 
 ≥ 3 29.0 (554) 24.7 (996) 
Missing 0 (0) 1.6 (64) 
   
Menopausal status, % (N)   
 premenopausal 44.9 (858) 49.0 (1,971) 
 postmenopausal 55.1 (1,052) 51.0 (2,054) 
   
Hormone replacement therapy, % (N)   
 never 79.7 (1,523) 68.9 (2,772) 
 former 15.9 (303) 20.8 (837) 
 current 4.4 (84) 5.0 (201) 
 missing 0 (0) 5.3 (215) 
   
Benign breast disease, % (N)   
 no 78.7 (1,503) 76.5 (3,080) 
 yes 21.3 (407) 21.3 (857) 
 missing 0 (0) 2.2 (88) 
   
Percent dense volume (%) * 7.8 (4.5-11.2) 8.4 (5.1-11.7) 
Absolute dense volume (cm3) * 57 (54-60) 60 (57-63) 
Absolute nondense volume (cm3) * 662 (658-666) 646 (642-649) 
   
Sister relatedness, % (N)   
 Full-sibling 95.1 (1,816)  
 Half-sibling 4.9 (94)  
 
Values are expressed as mean (SD), unless stated otherwise. *Geometric mean (95% CI). Study populations; 
Karma sisters = Karma sib-pair sample; Karma iCOGS = Karma sample of unrelated women genotyped on the 
custom Illumina iSelect genotyping (iCOGS) array.  
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Table 2. Intraclass correlation coefficients (ICC) and heritability estimates (h2) for volumetric mammographic measures.  
 
Sib-pair N pairs  
  ICC (SE) 
Full-sisters 908 Percent dense volume Absolute dense volume Absolute nondense volume 
Model 1  0.30 (0.03) 0.21 (0.03) 0.31 (0.03) 
Model 2  0.30 (0.03) 0.22 (0.03) 0.30 (0.03) 
Model 3  0.31 (0.03) 0.21 (0.03) 0.30 (0.03) 
Half-sisters 47    
Model 1  0.19 (0.14) 0.10 (0.14) 0.08 (0.14) 
Model 2  0.17 (0.14) 0.09 (0.14) 0.08 (0.14) 
Model 3  0.16 (0.14) 0.11 (0.14) 0.07 (0.14) 
     
  h2 (SE) 
Full and half-sister pairs 955 Percent dense volume Absolute dense volume Absolute nondense volume 
Model 1  0.62 (0.06) 0.43 (0.06) 0.61 (0.06) 
Model 2  0.60 (0.06) 0.43 (0.06) 0.61 (0.06) 
Model 3  0.63 (0.06) 0.43 (0.06) 0.61 (0.06) 
 
Abbreviations: ICC = intraclass correlation coefficient; h
2 
= heritability estimate; SE = standard error. 
All mammographic measures were log-transformed prior to analyses to approximate the normal distribution.  
Model 1: adjusted for age (years) and menopausal status (postmenopausal vs. premenopausal) 
Model 2: adjusted for age (years), menopausal status (postmenopausal vs. premenopausal) and BMI (kg/m
2
) 
Model 3: adjusted for age (years), menopausal status (postmenopausal vs. premenopausal), BMI (kg/m
2
), age at menarche (years), number of births and age at first birth 
(nulliparous, 1 child age at first birth < 25 years, 1 child age at first birth ≥ 25 years, 2 children age at first birth < 25 years, 2 children age at first birth ≥ 25 years, ≥ 3 children 
age at first birth < 25 years, ≥ 3 children age at first birth ≥ 25 years), HRT status (never, former, current) and benign breast disease (yes vs. no).  
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Table 3. Associations between breast cancer single nucleotide polymorphisms  and volumetric mammographic measures (N = 4,025)  
 
CHR Locus  SNP Alleles * MAF Percent dense volume Absolute dense volume Absolute nondense volume 
     Beta (SE) P Beta (SE) P Beta (SE) P 
1 PEX14 rs616488 G/A 0.32 0.01 (0.01) 0.26 -0.01 (0.01) 0.29 -0.02 (0.01) 0.02 
1 1p13.2 rs11552449 T/C 0.17 -0.01 (0.01) 0.55 -0.02 (0.01) 0.07 -0.02 (0.01) 0.17 
1 1p11.2  rs11249433 G/A 0.39 -0.01 (0.01) 0.24 0.01 (0.01) 0.31 0.02 (0.01) 0.02 
1 LGR6 rs6678914  A/G 0.43 0.00 (0.01) 0.98 0.00 (0.01) 0.64 0.00 (0.01) 0.73 
1 MDM4 rs4245739 C/A 0.24 0.01 (0.01) 0.13 0.01 (0.01) 0.50 -0.01 (0.01) 0.42 
2 2p24.1 rs12710696 T/C 0.35 0.01 (0.01) 0.42 0.00 (0.01) 0.71 -0.01 (0.01) 0.24 
2 2q14 rs4849887 T/C 0.09 0.01 (0.01) 0.52 0.04 (0.02) 0.01 0.03 (0.02) 0.04 
2 2q31.1 rs2016394 A/G 0.48 0.00 (0.01) 0.91 0.01 (0.01) 0.12 0.02 (0.01) 0.07 
2 CDCA7 rs1550623 G/A 0.15 0.00 (0.01) 0.93 -0.01 (0.01) 0.51 -0.01 (0.01) 0.46 
2 ERBB4  rs13393577 † C/T 0.11 0.03 (0.03) 0.23 0.04 (0.04) 0.25 0.00 (0.03) 0.98 
2 2q35 rs13387042 A/G 0.49 -0.01 (0.01) 0.17 -0.01 (0.01) 0.32 0.00 (0.01) 0.73 
2 DIRC3 rs16857609 T/C 0.28 0.01 (0.01) 0.23 0.03 (0.01) 0.01 0.01 (0.01) 0.15 
3 ITPR1 rs6762644 G/A 0.42 -0.01 (0.01) 0.43 0.01 (0.01) 0.54 0.01 (0.01) 0.13 
3 SLC4A7 rs4973768 T/C 0.45 0.00 (0.01) 0.93 0.00 (0.01) 0.81 0.00 (0.01) 0.84 
3 TGFBR2 rs12493607 C/G 0.37 0.00 (0.01) 0.76 0.00 (0.01) 0.88 0.00 (0.01) 0.68 
4 TET2 rs9790517 T/C 0.25 0.03 (0.01) 0.01 0.03 (0.01) 4.9x10-3 0.00 (0.01) 0.76 
4 ADAM29 rs6828523 A/C 0.12 0.00 (0.01) 0.87 -0.01 (0.02) 0.45 -0.01 (0.01) 0.53 
5 TERT rs10069690 T/C 0.27 -0.01 (0.01) 0.60 0.01 (0.01) 0.42 0.01 (0.01) 0.16 
5 TERT  rs2736108 T/C 0.29 -0.01 (0.01) 0.46 -0.01 (0.01) 0.17 -0.01 (0.01) 0.47  
5 5p12 rs4415084 T/C 0.40 0.01 (0.01) 0.54 0.00 (0.01) 0.70 -0.01 (0.01) 0.27 
5 5p12 rs10941679 G/A 0.25 0.01 (0.01) 0.30 0.00 (0.01) 0.87 -0.01 (0.01) 0.18 
5 MAP3K1  rs889312 C/A 0.28 -0.02 (0.01) 0.08 -0.01 (0.01) 0.31 0.01 (0.01) 0.46 
5 RAB3C  rs10472076 C/T 0.38 0.01 (0.01) 0.18 0.02 (0.01) 0.03 0.01 (0.01) 0.43 
5 PDE4D rs1353747 G/T 0.09 0.00 (0.02) 0.88 -0.03 (0.02) 0.07 -0.03 (0.02) 0.07 
5 EBF1 rs1432679 C/T 0.44 0.02 (0.01) 0.01 0.03 (0.01) 0.01 0.00 (0.01) 0.87 
6 FOXQ1  rs11242675 † C/T 0.41 -0.02 (0.02) 0.23 0.00 (0.02) 0.98 0.02 (0.02) 0.19 
6 RANBP9  rs204247 G/A 0.44 0.01 (0.01) 0.49 0.01 (0.01) 0.16 0.01 (0.01) 0.38 
6 6q14.1  rs17530068  C/T 0.25 -0.01 (0.01) 0.44 0.00 (0.01) 0.95 0.01 (0.01) 0.43 
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Table 3. Continued. 
 
CHR Locus SNP Alleles * MAF Percent dense volume Absolute dense volume Absolute nondense volume 
     Beta (SE) P Beta (SE) P Beta (SE) P 
6 6q22.33  rs2180341 †  G/A 0.24 -0.01 (0.02) 0.77 -0.02 (0.02) 0.49 -0.01 (0.02) 0.60 
6 TAB2 rs9485372 † A/G 0.18 -0.09 (0.02) 1.8x10-5  -0.08 (0.03) 1.8x10-3  0.02 (0.02) 0.28 
6 CCDC170 rs3757318  A/G 0.06 0.03 (0.02) 0.11 0.06 (0.02) 1.9x10-3 0.03 (0.02) 0.11 
6 ESR1  rs2046210 A/G 0.33 0.01 (0.01) 0.27 0.04 (0.01) 4.6x10-4 0.02 (0.01) 0.01 
6 ESR1  rs9383938 T/G 0.07 0.02 (0.02) 0.20 0.07 (0.02) 2.6x10-4 0.04 (0.02) 0.01 
7 7q35  rs720475 A/G 0.23 0.01 (0.01) 0.28 0.01 (0.01) 0.21 0.00 (0.01) 0.87 
8 8p21.1  rs9693444 A/C 0.32 0.02 (0.01) 0.04 0.00 (0.01) 0.87 -0.02 (0.01) 0.05 
8 8q21.11  rs6472903 G/T 0.18 0.01 (0.01) 0.57 0.00 (0.01) 0.90 -0.01 (0.01) 0.46 
8 HNF4G  rs2943559 G/A 0.07 0.01 (0.02) 0.51 0.00 (0.02) 0.84 -0.02 (0.02) 0.36 
8 8q24 rs13281615 G/A 0.39 0.00 (0.01) 0.93 0.01 (0.01) 0.56 0.01 (0.01) 0.59 
8 8q24  rs1562430 C/T 0.45 0.00 (0.01) 0.65 0.01 (0.01) 0.39 0.00 (0.01) 0.64 
8 MIR1208 rs11780156 T/C 0.13 0.01 (0.01) 0.50 0.02 (0.01) 0.14 0.01 (0.01) 0.35 
9 CDKN2A/B rs1011970 T/G 0.17 0.00 (0.01) 0.69 -0.01 (0.01) 0.46 0.00 (0.01) 0.77 
9 9q31.2  rs10759243 A/C 0.28 0.00 (0.01) 0.93 0.00 (0.01) 0.83 0.00 (0.01) 0.87 
9 9q31 rs865686 G/T 0.39 0.01 (0.01) 0.44 0.00 (0.01) 0.86 -0.01 (0.01) 0.32 
10 MLLT10 rs7072776 A/G 0.28 0.01 (0.01) 0.16 0.02 (0.01) 0.05 0.01 (0.01) 0.50 
10 DNAJC1  rs11814448 † C/A 0.02 -0.06 (0.06) 0.33 0.03 (0.07) 0.64 0.07 (0.05) 0.14 
10 ZNF365 rs10822013 C/T 0.47 -0.03 (0.01) 1.5x10-3 -0.02 (0.01) 0.07 0.01 (0.01) 0.20 
10 ZNF365 rs10995190 A/G 0.16 -0.05 (0.01) 9.0x10-6  -0.07 (0.01) 8.9x10-7  -0.01 (0.01) 0.48 
10 ZMIZ1 rs704010 T/C 0.37 0.01 (0.01) 0.56 0.00 (0.01) 0.82 -0.01 (0.01) 0.38 
10 TCF7L2 rs7904519 G/A 0.44 -0.01 (0.01) 0.09 -0.01 (0.01) 0.20 0.00 (0.01) 0.72 
10 10q26.12  rs11199914 T/C 0.32 0.00 (0.01) 0.87 0.00 (0.01) 0.90 0.00 (0.01) 0.78 
10 FGFR2 rs2981579 A/G 0.39 0.00 (0.01) 0.69 0.00 (0.01) 0.86 -0.01 (0.01) 0.52 
11 LSP1 rs3817198 C/T 0.30 0.00 (0.01) 0.81 0.01 (0.01) 0.61 0.00 (0.01) 0.66 
11 11q13.1  rs3903072 T/G 0.47 0.00 (0.01) 0.59 0.01 (0.01) 0.35 0.00 (0.01) 0.64 
11 11q13 rs614367  T/C 0.15 -0.01 (0.01) 0.61 -0.01 (0.01) 0.32 -0.01 (0.01) 0.59 
11 11q13 rs78540526  T/C 0.08 -0.04 (0.03) 0.21 -0.01 (0.04) 0.77 0.02 (0.03) 0.41 
11 11q13 rs75915166  A/C 0.06 0.00 (0.02) 0.96 -0.01 (0.02) 0.76 -0.01 (0.02) 0.66 
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Table 3. Continued. 
 
CHR Locus SNP Alleles * MAF Percent dense volume Absolute dense volume Absolute nondense volume 
     Beta (SE) P Beta (SE) P Beta (SE) P 
11 11q24.3  rs11820646 T/C 0.43 -0.01 (0.01) 0.46 0.00 (0.01) 0.78 0.01 (0.01) 0.29 
12 12p13.1  rs12422552 C/G 0.25 0.01 (0.01) 0.42 0.02 (0.01) 0.17 0.01 (0.01) 0.53 
12 PTHLH  rs10771399 G/A 0.13 0.00 (0.01) 0.91 -0.02 (0.01) 0.17 -0.02 (0.01) 0.12 
12 NTN4  rs17356907 G/A 0.29 -0.02 (0.01) 0.01 0.01 (0.01) 0.24 0.04 (0.01) 8.4x10-5 
12 12q24 rs1292011 G/A 0.44 0.00 (0.01) 0.90 0.00 (0.01) 0.98 0.00 (0.01) 0.87 
13 BRCA2 rs11571833  T/A 0.008 -0.11 (0.10) 0.25 -0.05 (0.12) 0.67 0.07 (0.08) 0.43 
14 PAX9 rs2236007 A/G 0.21 0.00 (0.01) 0.97 0.00 (0.01) 0.75 0.00 (0.01) 0.77 
14 RAD51L1 rs2588809 T/C 0.15 -0.01 (0.01) 0.25 -0.01 (0.01) 0.38 0.00 (0.01) 0.86 
14 RAD51L1 rs999737 T/C 0.22 -0.01 (0.01) 0.38 -0.01 (0.01) 0.51 0.00 (0.01) 0.83 
14 CCDC88C rs941764 G/A 0.33 0.00 (0.01) 0.87 -0.01 (0.01) 0.26 -0.01 (0.01) 0.25 
16 TOX3  rs3803662 A/G 0.25 0.00 (0.01) 0.71 0.01 (0.01) 0.38 0.01 (0.01) 0.18 
16 TOX3  rs3112612 A/G 0.37 0.00 (0.01) 0.77 0.01 (0.01) 0.98 0.00 (0.01) 0.69 
16 FTO rs17817449 G/T 0.41 -0.01 (0.01) 0.37 -0.02 (0.01) 0.02 -0.01 (0.01) 0.13 
16 FTO rs11075995 A/T 0.26 0.00 (0.01) 0.63 0.00 (0.01) 0.66 -0.01 (0.01) 0.34 
16 CDYL2 rs13329835 G/A 0.21 0.00 (0.01) 0.95 0.00 (0.01) 0.75 0.00 (0.01) 0.77 
17 COX11  rs6504950 A/G 0.26 -0.03 (0.01) 2.8x10-3 -0.02 (0.01) 0.11 0.01 (0.01) 0.16 
18 18q11.2  rs527616 C/G 0.40 0.00 (0.01) 0.71 0.01 (0.01) 0.52 0.01 (0.01) 0.27 
18 CHST9 rs1436904 G/T 0.41 0.02 (0.01) 0.03 0.00 (0.01) 0.64 -0.02 (0.01) 0.08 
19 MERIT40  rs8170 A/G 0.19 0.01 (0.01) 0.50 0.02 (0.01) 0.21 0.01 (0.01) 0.56 
19 ANKLE1 rs8100241  G/A 0.47 -0.01 (0.01) 0.50 -0.01 (0.01) 0.41 0.00 (0.01) 0.79 
19 ELL rs4808801 G/A 0.35 -0.02 (0.01) 0.06 -0.02 (0.01) 0.08 0.00 (0.01) 0.94 
19 19q13.31  rs3760982 A/G 0.45 -0.01 (0.01) 0.16 -0.02 (0.01) 0.09 0.00 (0.01) 0.71 
20 RALY rs2284378 † T/C 0.30 -0.01 (0.02) 0.64 -0.01 (0.02) 0.64 0.00 (0.02) 0.98 
21 NRIP1  rs2823093 A/G 0.27 0.00 (0.01) 0.81 0.01 (0.01) 0.52 0.01 (0.01) 0.62 
22 EMID1 rs132390  C/T 0.04 -0.05 (0.04) 0.20 -0.07 (0.05) 0.21 0.00 (0.04) 0.99 
22 MKL1 rs6001930 C/T 0.12 0.01 (0.01) 0.34 -0.05 (0.02) 9.0x10-4 -0.06 (0.01) 6.7x10-6 
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Abbreviations: CHR = chromosome; MAF = minor allele frequency: SE = standard error. * Alleles: minor/major allele.  † Imputed SNPs with info-score > 0.80. All SNP 
association tests were performed under the additive model with betas representing the per-minor allele increase in log volumetric mammographic measures, adjusted for 
age (years), body mass index (kg/m
2
) and menopausal status (postmenopausal vs. premenopausal). Statistically significant associations in bold.  SNP rs10483813 in RAD51L1 
was replaced by rs999737, as this is the index SNP identified by iCOGS (11). Linked SNPs: TERT: rs10069690 and rs2736108 r
2
=0.13; 5p12: rs4415084 and rs10941679 
r2=0.60; ESR1: rs3757318 and rs2046210 r
2
=0.07; rs3757318 and rs9383938 r
2
=0.44; rs2046210 and rs9383938 r
2
=0.12; 8q24: rs13281615 and rs1562430 r2=0.47; ZNF365:  
rs10995190 and rs10822013 r
2
=0.15; 11q13: rs614367 and rs78540526 r2=0.38; rs614367 and rs75915166 r
2
=0.37; rs78540526 and rs75915166 r
2
=0.58; TOX3: rs3803662 
and rs3112612 r
2
=0.15.   
 
